NCT04054362 - Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Pancreatic Cancer

Interventions

DRUG

Paclitaxel protein bound

paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

DRUG

Cisplatin

paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

DRUG

Gemcitabine

paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

DRUG

Paricalcitol

paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Trial Locations (1)

Barts Health NHS Trust, London

All Listed Sponsors

lead

Barts & The London NHS Trust

OTHER